NYSEAMERICAN:MTNB - Matinas BioPharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.10 +0.10 (+10.00 %) (As of 01/18/2019 12:43 PM ET)Previous Close$1.00Today's Range$0.99 - $1.1352-Week Range$0.32 - $1.48Volume30,810 shsAverage Volume1.48 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey. Receive MTNB News and Ratings via Email Sign-up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:MTNB Previous Symbol CUSIPN/A Webwww.matinasbiopharma.com Phone+1-908-4431860Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees15 Outstanding Shares112,390,000Market Cap$0.00 OptionableNot Optionable Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions What is Matinas BioPharma's stock symbol? Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB." How were Matinas BioPharma's earnings last quarter? Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) released its quarterly earnings data on Monday, November, 12th. The company reported ($0.03) EPS for the quarter. View Matinas BioPharma's Earnings History. When is Matinas BioPharma's next earnings date? Matinas BioPharma is scheduled to release their next quarterly earnings announcement on Monday, March 25th 2019. View Earnings Estimates for Matinas BioPharma. What price target have analysts set for MTNB? 1 brokers have issued 12-month price objectives for Matinas BioPharma's shares. Their predictions range from $5.00 to $5.00. On average, they anticipate Matinas BioPharma's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 354.5% from the stock's current price. View Analyst Price Targets for Matinas BioPharma. What is the consensus analysts' recommendation for Matinas BioPharma? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Matinas BioPharma. Has Matinas BioPharma been receiving favorable news coverage? News articles about MTNB stock have been trending somewhat positive on Friday, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Matinas BioPharma earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. Are investors shorting Matinas BioPharma? Matinas BioPharma saw a increase in short interest in December. As of December 31st, there was short interest totalling 4,100,334 shares, an increase of 6.8% from the December 14th total of 3,839,495 shares. Based on an average trading volume of 923,214 shares, the short-interest ratio is currently 4.4 days. Approximately 4.4% of the shares of the stock are short sold. View Matinas BioPharma's Current Options Chain. Who are some of Matinas BioPharma's key competitors? Some companies that are related to Matinas BioPharma include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE) and Ampliphi Biosciences (APHB). Who are Matinas BioPharma's key executives? Matinas BioPharma's management team includes the folowing people: Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 44)Dr. Raphael J. Mannino, Sr. VP & Chief Scientific Officer (Age 71)Dr. Theresa Matkovits, Chief Devel. Officer (Age 51)Mr. Frank Calamusa, Exec. Director and Head of Manufacturing & Supply ChainDr. Jenel Cobb, Director of Project Management Who are Matinas BioPharma's major shareholders? Matinas BioPharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.06%). Company insiders that own Matinas BioPharma stock include Adam K Stern, James S Scibetta and Roelof Rongen. View Institutional Ownership Trends for Matinas BioPharma. Which major investors are buying Matinas BioPharma stock? MTNB stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Matinas BioPharma stock in the last two years include Adam K Stern, James S Scibetta and Roelof Rongen. View Insider Buying and Selling for Matinas BioPharma. How do I buy shares of Matinas BioPharma? Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Matinas BioPharma's stock price today? One share of MTNB stock can currently be purchased for approximately $1.10. What is Matinas BioPharma's official website? The official website for Matinas BioPharma is http://www.matinasbiopharma.com/. How can I contact Matinas BioPharma? Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860. MarketBeat Community Rating for Matinas BioPharma (NYSEAMERICAN MTNB)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 156 (Vote Outperform)Underperform Votes: 119 (Vote Underperform)Total Votes: 275MarketBeat's community ratings are surveys of what our community members think about Matinas BioPharma and other stocks. Vote "Outperform" if you believe MTNB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTNB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/18/2019 by MarketBeat.com StaffFeatured Article: How does inflation affect different investments?